Tempest Therapeutics director granted 1,230 options

Tempest Therapeutics director Ronit Simantov received a stock option grant for 1,230 shares on January 27, 2026.

Rhea-AI Filing Summary

Tempest Therapeutics director Ronit Simantov received a stock option grant for 1,230 shares on January 27, 2026. The option has an exercise price of $2.94 per share and was granted at no cost. It will vest in full on the earlier of January 27, 2027, or the company’s 2026 annual stockholder meeting, provided Simantov continues serving through that date.

Insider Trade Summary

Grant/Award: 1,230 shares

Grant/Award 1 txn

Insider Simantov Ronit

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	1,230	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 1,230 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tempest Therapeutics (TPST) report for Ronit Simantov?

Tempest Therapeutics reported a stock option grant to director Ronit Simantov. She received options to buy 1,230 shares on January 27, 2026, at an exercise price of $2.94 per share, with no cost for receiving the option itself.

How many Tempest Therapeutics stock options were granted to director Ronit Simantov?

Ronit Simantov was granted options covering 1,230 Tempest Therapeutics shares. These options were acquired in a single transaction and represent her entire reported derivative holdings following the grant, according to the Form 4 filing for January 27, 2026.

What is the exercise price of Ronit Simantov’s Tempest Therapeutics stock options?

The exercise price of Ronit Simantov’s Tempest Therapeutics stock options is $2.94 per share. This means she can purchase up to 1,230 shares at $2.94 each once the options vest, regardless of the market price at that time.

When do Ronit Simantov’s Tempest Therapeutics stock options vest?

Ronit Simantov’s options vest in full on the earlier of January 27, 2027, or the day of Tempest Therapeutics’ 2026 annual stockholder meeting. Vesting is conditioned on her continuous service with the company through the applicable vesting date.

Is Ronit Simantov’s Tempest Therapeutics option grant a direct or indirect holding?

Ronit Simantov’s Tempest Therapeutics option grant is reported as a direct holding. The Form 4 indicates the 1,230 derivative securities are owned directly, with no separate entity or indirect beneficial ownership structure described in the filing.

How many derivative securities does Ronit Simantov own in Tempest Therapeutics after this grant?

After this grant, Ronit Simantov beneficially owns 1,230 derivative securities in Tempest Therapeutics. These represent stock options giving her the right to buy an equal number of common shares once the options become fully vested under the disclosed schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/28/2026 - 04:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simantov Ronit

(Last) (First) (Middle)

C/O TEMPEST THERAPEUTICS, INC.

2000 SIERRA POINT PARKWAY, SUITE 400

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tempest Therapeutics, Inc. [ TPST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.94	01/27/2026		A		1,230		(1)	01/26/2036	Common Stock	1,230	$0	1,230	D

Explanation of Responses:

1. The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Nicholas Maestas, Attorney-in-Fact	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.